Canada’s paid-plasma program faces scrutiny after allegations of exploitation and unsafe practices. Critics argue the system prioritizes profit over patient safety, while donors report severe health complications. Health authorities investigate potential links between commercial plasma collection and adverse donor outcomes.
Provincial and territorial health officials raise concerns about the safety of private plasma donation sites in Canada after a second donor death in Winnipeg. The officials have submitted urgent questions to Health Canada regarding the frequency and oversight of these donations. The incidents occurred at privately operated collection facilities, prompting regulatory scrutiny.
Health Canada reports Grifols misclassified serious adverse reactions linked to plasma donations at its clinics. The incidents were initially attributed to donations but later reclassified by the company. The agency highlights discrepancies in reporting medical outcomes tied to plasma collection procedures.
For-profit plasma donation centers account for nearly all serious adverse reactions among donors over the past decade, according to CBC News data. Multiple individuals suffered life-threatening conditions, hospitalizations, or required medical intervention after donating. The incidents highlight systemic risks tied to commercial plasma collection operations.
Grifols, a global leader in plasma-derived medicines, acquires its first plasma donation center in Canada. The move expands the company’s access to plasma supplies, supporting its production of life-saving therapies. Grifols aims to strengthen its presence in the Canadian healthcare market through this strategic acquisition.
Liminal BioSciences sells its plasma collection centers in Winnipeg, Manitoba, and Amherst, New York, to Kedrion. The deal includes subsidiaries Prometic Plasma Resources Inc. and Prometic Plasma Resources (USA) Inc., covering plasma-derived therapeutics operations. Kedrion acquires the assets through a binding Share Purchase Agreement.
Prometic Life Sciences demonstrates plasma collection and processing capabilities at its Winnipeg facility. The company highlights advancements in biomanufacturing for therapeutic applications, leveraging its expertise in plasma-derived products. Prometic’s work focuses on developing treatments using human plasma components.
ProMetic Life Sciences Inc. acquires Emergent BioSolutions’ plasma collection center in Winnipeg, Canada. The deal involves the transfer of a facility supporting plasma-based biopharmaceutical production. Terms are subject to standard closing conditions.